# ETX-880

Source: https://onco.cc/drugs/etx-880/  
OnCo record `etx-880` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ETX-880 is an experimental small molecule from Ensem Therapeutics, in preclinical development for MSI-high colorectal cancer, MSI-high gastric cancer and MSI-high endometrial cancer.

## Summary

ETX-880 is a small molecule (oral, covalent) from Ensem Therapeutics. An oral, selective covalent inhibitor of Werner helicase (WRN), being developed for microsatellite instability-high cancers. Its furthest stage is preclinical development, for MSI-high colorectal cancer, MSI-high gastric cancer and MSI-high endometrial cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline page describes only in vitro and xenograft data; no ClinicalTrials.gov record for ETX-880. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: ETX-880
- Modality: Small molecule (oral, covalent)
- Mechanism: An oral, selective covalent inhibitor of Werner helicase (WRN), being developed for microsatellite instability-high cancers.

## Sources

- Ensem Therapeutics: ensemtx.com: https://ensemtx.com/science/pipeline/
- Ensem Therapeutics: ensemtx.com: https://ensemtx.com/science/pipeline/

## Connected records

- targets: [WRN helicase (MSI-high cancers)](https://onco.cc/targets/wrn/)
- companies: [Ensem Therapeutics](https://onco.cc/companies/ensem-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/etx-880.json